ClinicalTrials.gg
CompletedNCT03335839STRIVEUpdated Jun 18, 2026

Adjunctive, Low-dose tPA in Primary PCI for STEMI

A Phase 3 interventional study of tissue plasminogen activator and Saline in Myocardial Infarction and Percutaneous Coronary Intervention, sponsored by Population Health Research Institute. Completed at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Population Health Research Institute · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 171 studies in Myocardial Infarction with a site in Canada — 18 open to participants now, 30 under way, 9 of them phase 3. Myocardial Infarction · Canada.

Enrollment
86th of 135
210 · median 500
Started
2018
with 9 others
Phase 3
45 of 171
5 open now
Registered
121st of 171
by date
Lead sponsor
7 of 171
Population Health Research Institute

Among the 171 studies in Myocardial Infarction with a site in Canada, this one is the 86th largest by enrollment of the 135 interventional ones that give a count, is one of 10 that started in 2018, is one of 45 in phase 3, and was the 121st registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

18 of the 171 studies in Myocardial Infarction with a site in Canada are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Myocardial Infarction with a site in Canada, or all of them as a file.
02

Study summary

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.

Read the detailed description

STRIVE is a prospective, 3-arm, parallel group, blinded, randomized controlled trial evaluating the efficacy of a novel approach to prevent and treat microvascular obstruction thereby reducing major cardiovascular events using intracoronary administration of very low-dose fibrinolytic (tissue plasminogen activator, tPA) directly into the culprit coronary artery during primary PCI.

03

Conditions studied

  • Myocardial Infarction
  • Percutaneous Coronary Intervention

Keywords

  • tPA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with STEMI undergoing primary PCI and,
  2. changes indicating large territory STEMI (defined as ≥2mm ST-segment elevation in 2 contiguous anterior precordial leads; or ≥2mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥8mm) and,
  3. Randomization within 6 to 12 hours of symptom onset and,
  4. Large thrombus burden with angiographic TIMI Thrombus Grade ≥3 after guidewire crossing.

Exclusion criteria

Exclusion Criteria:

  1. Active internal bleeding or high risk of bleeding or any prior intracranial bleeding.
  2. Any other absolute or relative to fibrinolytic therapy.
  3. Administration of a fibrinolytic ≤24hrs prior to randomization.
  4. Cardiogenic shock on presentation.
  5. Left bundle branch block (excluded because the cannot be evaluated for ST segment resolution, an outcome of the study).
  6. Planned upfront use of a glycoprotein IIb/IIIa inhibitor.
  7. Any medical, geographic, or social factor making study participation impractical or precluding 1 month follow-up.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Intracoronary tPA 10 mg

    Drug: tissue plasminogen activator

  • Experimental
    Intracoronary tPA 20 mg

    Drug: tissue plasminogen activator

  • Placebo comparator
    Placebo

    saline

    Other: Saline

Interventions

  • Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.

  • OtherSaline

    Placebo

06

What researchers measure

Primary outcomes

  1. MACE OR Myocardial Blush Grade 0/1 OR Distal Embolization OR Failure to Achieve ≥50% ST-segment Resolution

    The primary efficacy variable is the binary composite outcome with the following components: * The occurrence of any of the MACE outcomes (cardiovascular death, myocardial re-infarction, cardiogenic shock and new onset heart failure) at 30 days post-randomization. * Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)). * Post-procedural Distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI). * Failure to achieve ≥50% ST-segment resolution post-procedure.

    Time frame: 30 days post-randomization

Secondary outcomes

  1. The Composite of MBG grade 0/1 or Distal Embolization or Failure to Achieve ≥50% ST-segment Resolution

    * Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)). * Post-procedural Distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI). * Failure to achieve ≥50% ST-segment resolution post-procedure of the summed absolute ST-segment deviations across associated and reciprocal leads at 30 minutes post-PCI

    Time frame: 30 minutes post-PCI

  2. The Composite of MBG grade 0/1 or Distal Embolization

    * Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)). * Post-procedural Distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI).

    Time frame: Immediately following PCI

  3. MBG Grade 0/1

    Post-procedural Myocardial Blush Grade of either 0 (Failure of dye to enter the microvasculature or persistent "staining", suggesting leakage of the contrast medium into the extravascular space) or 1 (Dye enters slowly but fails to exit the microvasculature. Dye is present in the next injection (30 seconds)).

    Time frame: Immediately following PCI

  4. Distal Embolization

    Post-procedural distal embolization, defined as distal filling defect with an abrupt 'cut-off' in one of the peripheral coronary branches of the infarct related artery, distal to the angioplasty site following PCI.

    Time frame: Immediately following PCI

  5. Failure to Achieve ≥50% ST-segment Resolution.

    Failure to achieve ≥50% ST-segment resolution of the summed absolute ST-segment deviations across associated and reciprocal leads at 30 minutes post-PCI.

    Time frame: 30 minutes post-PCI

  6. Time to the First Occurrence of MACE

    Time to the first occurrence of MACE (composite of cardiovascular death, myocardial re-infarction, cardiogenic shock or new onset heart failure) over the duration of 30 days follow-up.

    Time frame: 30 days post-randomization

Other outcomes

  1. Time to the First Occurrence of Major Bleeding Over the Duration of 30 Days Follow-up

    Clinically overt, bleeding with at least one of the following criteria: * Fatal or * Symptomatic intracranial hemorrhage or * Retroperitoneal hemorrhage or * Intraocular hemorrhage leading to significant vision loss or * Decrease in hemoglobin of ≥ 3.0 g/dL (with each blood transfusion unit counting for 1.0 g/dL of hemoglobin or requiring transfusion of two or more units of red blood cells or equivalent of whole blood) or * Requiring surgical intervention to stop the bleeding

    Time frame: 30 days post-randomization

  2. Time to the First Occurrence of Major or Clinically Significant Bleeding Over the Duration of 30 Days Follow-up

    Clinically overt, bleeding with at least one of the following criteria: * Fatal or * Symptomatic intracranial hemorrhage or * Retroperitoneal hemorrhage or * Intraocular hemorrhage leading to significant vision loss or * Decrease in hemoglobin of ≥ 3.0 g/dL (with each blood transfusion unit counting for 1.0 g/dL of hemoglobin or requiring transfusion of two or more units of red blood cells or equivalent of whole blood) or * Requiring surgical intervention to stop the bleeding Any other clinically significant bleeding not meeting the definition for major bleeding and resulting in hospital admission, prolonged hospital stay or transfusion of one unit of blood (whole blood or packed red blood cells (PRBC))

    Time frame: 30 days post-randomization

  3. Failure to achieve ≥ 50% resolution

    Failure to achieve ≥ 50% resolution of the ST-segment value (worst lead) at 30 minutes post-PCI

    Time frame: 30 minutes post-PCI

  4. All-Cause Mortality at 30 Days

    The composite of cardiovascular or non-cardiovascular death

    Time frame: 30 days post-randomization

  5. Flow Velocity as Measured by the Corrected TIMI Frame Count (Continuous)

    Continuous measure of TIMI frame count as reported by Angiographic Core Lab.

    Time frame: Immediately following PCI

  6. Post-Procedural TIMI Flow Grade 3

    Full perfusion of the infarct vessel with normal flow.

    Time frame: Immediately following PCI

  7. Time to the First Occurrence of Composite of Cardiovascular Death (CV), Cardiogenic Shock and New Onset Heart Failure (HF) Over the Duration of 30 Days Follow-up

    All deaths with a CV or unknown cause will be classified as CV. Only deaths due to a documented non-CV cause will be classified as non-CV. At least one of the following: * SBP \<90mmHg and not responsive to fluid resuscitation and/or HR correction for at least 1 hr * Need for vasopressor/inotropic therapy to maintain SBP \>90mmHg for at least 1 hr, believed to be secondary to cardiac dysfunction and associated with Pulmonary edema/Hypoperfusion/Cardiac Index \<2.0L/min New onset HF as per NYHA and defined as decision to treat with IV diuretic, inotropic agent or vasodilator with at least one of the following: presence of pulmonary edema or pulmonary vascular congestion on chest radiograph thought to be due to HF / râles reaching above the lower 1/3 of the lung fields thought to be due to HF / pulmonary capillary wedge pressure or left ventricular end-diastolic pressure = 18mmHg. In the case of new onset outpatient HF, re-admission to an acute care facility is required.

    Time frame: 30 days post-randomization

07

Study locations

3 sites
  • University of Calgary - Foothills Medical Centre
    Calgary, Alberta T2N 4Z6, Canada
  • University of Alberta - Mazankowski Alberta Heart Insitute
    Edmonton, Alberta T6G 2B7, Canada
  • Hamilton General Hospital
    Hamilton, Ontario L8L2X2, Canada
08

References and documents

Publications

  • Mehta SR, Pinilla-Echeverri N, Tiong D, Kovalova T, Sheth T, Natarajan MK, Sibbald M, Velianou JL, Welsh R, Har B, Jolly SS, Valettas N, Schwalm JD, Tsang M, Khatun R, Mian R, Cunningham J, Ly E, McCready T, Bainey KR. Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial. J Am Coll Cardiol. 2026 Jan 27;87(3):238-248. doi: 10.1016/j.jacc.2025.10.008. Epub 2025 Oct 28. PubMed 41194755 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Sep 2024, 77 months.

Of 34 non-industry phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 73. This study's 77 months is above that.

Counting every sponsor, half of 58 studies reached it within 44 months; a quarter within 30 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2017
First posted
Nov 8, 2017
StartActual
Apr 1, 2018
Primary completionActual
Sep 17, 2024
CompletionActual
Feb 12, 2025
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03335839
Collaborators
Heart and Stroke Foundation of Canada
Responsible party
Sponsor
First posted
Nov 8, 2017
Start date
Apr 1, 2018
Primary completion
Sep 17, 2024
Completion
Feb 12, 2025
Last update
Jun 18, 2026

Study contacts

Shamir Mehta, MD
principal investigator · McMaster University, Hamilton Health Sciences, Population Health Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tissue Plasminogen Activator

Start the discussion